MedWatch

daratumumab

Her finder du de seneste artikler om daratumumab fra MedWatch, der leverer troværdige, uafhængige, kritiske og fair erhvervsnyheder om daratumumab og andre danske og internationale medicinalprodukter.

Genmab står på spring til kæmpe marked

Genmab og partneren Janssen Biotech er torsdag kommet et stort skridt nærmere at gøre kræftmidlet Darzalex til den succes, som analytikere for længst har skrevet ind i deres regneark.

Genmab prepares for a slew of clinical studies

Danish biotech Genmab could be earning billions from its J&J-partnered cancer drug Darzalex in coming years, and the firm will use a chunk of that cash to begin clinical studies with a number of new candidates. The first of these has already moved into the clinic.

Genmab-middel får særstatus i USA

De amerikanske lægemiddelmyndigheder, FDA, har givet danske Genmab en særstatus til kombinationsbehandlinger, der involverer guldægget daratumumab (Darzalex).

Darzalex har fået en god pris i Europa

Selvom det amerikanske marked som altid er vigtigst, er det absolut ikke uinteressant med den nye udvidede ansøgning på Genmabs knoglemarvskræft-produkt i Europa, hvor midlet er blevet højere prissat end ventet.

How Genmab’s cancer hope became a golden ticket

This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. Over the course of seven chapters we give you the full story about what turned out to be the biggest biotech success ever on Danish ground

Popping the cork

Chapter 7. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This is the seventh and final installment about the culmination of ten years hard work.

Management wants to kill off dara – more than once

Chapter 5. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. The fifth installment details how the drug only exists today because of a certain Dutch exec who puts up a fight when the rest of the management team tries to shelve the drug on more than one occasion.

“We were scared patients would bleed out”

Chapter 4. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This third installment details how the first doses given to patients were little more than water, as there was a real fear of damage to the body’s cells.

Daratumumab requires additional monkey studies

Chapter 3. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This third installment is about how Genmab is forced to conduct additional toxicity studies to establish the safety of the drug.

The golden ticket is placed in Utrecht

Chapter 2. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This second installment deals with how daratumumab is picked from a field of hundreds of antibodies in a lab in the Dutch city of Utrecht.

”Don, why don’t we form a company?”

Chapter 1. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This first installment looks at the biotech’s humble beginnings and why the company, according to major investor Florian Schönharting, is currently worth 10 billion dollars less than it could have been.

EMA bakker op om Genmabs kræftmiddel

Det europæiske ekspertpanel CHMP under Det Europæiske Lægemiddelagentur har anbefalet de europæiske myndigheder at give en betinget godkendelse af Genmab-kræftmidlet Darzalex.

”It could be the beginning of a new era for daratumumab”

Genmab’s CEO is extremely thrilled with a new partnership between Janssen and Roche as it could pave the way for a new market for the Genmab-developed drug daratumumab – a market that could exceed the value of the current billion-dollar market.

Analytiker: Tillidserklæring til Genmab

Det er ifølge Jyske Bank-analytiker Frank Hørning Andersen en bekræftelse af potentialet og en tillidserklæring til daratumumab, at Janssen og Roche har indledt et nyt klinisk studie uden for multipel myelomatose.

Genmab topper afkast i dansk life science

Biotekselskabet Genmab topper den danske børsnoterede life science-branche, når man kigger på årlige afkast fordelt på de sidste fem år, viser en analyse foretaget af MedWatch. Mens de enkelte sektorer ligger overraskende tæt afkastmæssigt, så underpræsterer høreapparatselskaberne dog.

Nordea følger trop - hæver kursmål på Genmab

Som flere andre er også Nordeas analytiker blevet imponeret over Genmabs Darzalex på den netop overståede cancerkonference ASH. Hos Nordea peger man dog også på et øget potentiale hos et af Genmabs andre lægemidler.

Danske: Genmab-middel tromler modstand ned

Den nyligt overståede ASH-konference i Florida har kun styrket Danske Capitals seniorporteføljeforvalter i troen på Genmab-midlet daratumumab. Han peger blandt andet på læger, som snakker om meget mere udbredt brug af midlet, off-label-brug, attraktiv prissætning, og en fremtidig standardbehandling med det dansk-udviklede middel som rygrad.

1 - 25 af 122 Næste side

Seneste nyt

Ledige job

Se flere

Se flere

Latest news

Seneste nyt fra Watch Medier